

January 30, 2017

Subject: Report of the utilization of capital increase from IPO.

To: President
The Stock Exchange of Thailand

With reference to Mega Lifesciences Public Company Limited ("The Company") issued new shares for capital increase by initial public offering ("IPO") for 129.79 million shares during the period at November 11-13, 2013 at the price of Baht 17.50 per share, totaling net amount of Baht 2,225.8 million after deduction of underwriting fee in connection with the offering.

The company would like to summarize and report utilization of capital increase from IPO at the end of December 31, 2016 as following

Unit: THB mm

Objective	Plan of Proceed	Actual Spending Until 31 December, 2016	Remaining Amount
Repayment of loan from financial institution	1,500.0-1,700.0	1,142.5	357.5-557.5
Working capital and future business expansion	525.8-725.8	481.1	44.7-244.7
Total Proceed	2,225.8	1,623.6	602.2

Amount of Thai Baht 326.0 Million was used to partially fund the 'Biolife' Acquisition announced in November 2016 and the fund utilization has been reported under Working capital / Future Business expansion above.

Please be informed accordingly,

Your faithfully,


(Mr. Thomas Abraham)

Director and Chief Financial Officer

**MEGA LIFESCIENCES Public Company Limited**384 Moo 4, Pattana 3 Road, Bangpoo Industrial Estate,
Soi 6, Preaksa, Muang Samutprakarn,
Samutprakarn 10280, Thailand

Telephone +66 (0)2 401 8686 Fax +66 (0)2 324 0451

info@megawecare.com

www.megawecare.com